for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

FUJIFILM Holdings Corp

4901.T

Latest Trade

5,625.00JPY

Change

-105.00(-1.83%)

Volume

2,576,200

Today's Range

5,596.00

 - 

5,754.00

52 Week Range

4,152.00

 - 

6,420.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
5,730.00
Open
5,750.00
Volume
2,576,200
3M AVG Volume
35.14
Today's High
5,754.00
Today's Low
5,596.00
52 Week High
6,420.00
52 Week Low
4,152.00
Shares Out (MIL)
399.77
Market Cap (MIL)
2,948,806.00
Forward P/E
18.01
Dividend (Yield %)
1.66

Next Event

Q3 2021 Fujifilm Holdings Corp Earnings Release

Latest Developments

More

Lonza Announces Collaboration With Fujifilm Cellular Dynamics

Dr. Reddy's Prices COVID-19 Drug Avigan (Favipiravir) at 99 Rupees/Tablet

Fujifilm Says Delay In Completion Schedule For Acquisition Of Diagnostic Imaging-Related Business From Hitachi

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About FUJIFILM Holdings Corp

FUJIFILM Holdings Corporation is a Japan-based holding company engaged in the business related to photography, medical care & printing & liquid crystal display materials and copying machines. The Company operates in three business segments. Imaging Solutions segment develops, manufactures and sells color films, digital cameras, color paper services for photographic prints, instant printing equipment and optical devices mainly for general consumers. Healthcare & Materials Solutions segment provides medical system equipment, cosmetics and supplements, pharmaceutical products, biopharmaceutical manufacturing development contract, regenerative medicine products, chemical products, graphic system equipment, inkjet equipment, display materials, recording media and electronic materials for commercial use. Document Solutions segment provides digital multi-functional peripherals, publishing systems, document management software and related solution services mainly for commercial use.

Industry

Medical Equipment & Supplies

Contact Info

Midtown West, 9-7-3, Akasaka

MINATO-KU, TKY

107-0052

Japan

+81.3.62711111

https://www.fujifilmholdings.com/ja/

Executive Leadership

Shigetaka Komori

Chairman of the Board, Group Chief Executive Officer, Chairman of Subsidiaries, Representative Director

Kenji Sukeno

President, Group Chief Operating Officer, President of Subsidiary, Representative Director

Koichi Tamai

Vice President, President of Subsidiary, Director

Chisato Yoshizawa

Executive Officer, Director of Human Resources

Takashi Iwasaki

Executive Officer, Chief Technical Officer, Director of Technology Business, Director

Key Stats

2.00 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2018

2.4K

2019

2.4K

2020

2.3K

2021(E)

2.2K
EPS (JPY)

2018

322.620

2019

326.810

2020

306.180

2021(E)

317.826
Price To Earnings (TTM)
17.68
Price To Sales (TTM)
1.35
Price To Book (MRQ)
1.14
Price To Cash Flow (TTM)
11.45
Total Debt To Equity (MRQ)
28.09
LT Debt To Equity (MRQ)
24.47
Return on Investment (TTM)
5.14
Return on Equity (TTM)
3.99

Latest News

Latest News

Fujifilm partners Shanghai firm to seek China COVID-19 approval for Avigan

Japan's Fujifilm Holdings Corp <4901.T> said on Thursday it has partnered with Shanghai-based Carelink Pharmaceutical Co to seek approval in China for Avigan to treat COVID-19 and influenza.

Fujifilm seeks approval for Avigan as COVID-19 treatment in Japan

Fujifilm Holdings Corp said on Friday it was seeking approval for its flu drug Avigan as a treatment for COVID-19 in Japan, a move that comes after a late-stage study showed reduced recovery time for patients with non-severe symptoms.

Fujifilm applies for approval of Avigan as COVID-19 treatment in Japan

Fujifilm Holdings Corp said on Friday it had applied for approval in Japan of its anti-influenza drug Avigan as a treatment for COVID-19.

Eli Lilly in deal to supply COVID-19 drugs to low-income countries

Eli Lilly and Co <LLY.N> said on Thursday it had entered into an agreement with the Bill & Melinda Gates Foundation for potential supply of its experimental antibody treatments for COVID-19 to low and middle-income countries.

Fujifilm signs manufacturing contract with U.S. firm VLP for COVID-19 vaccine

Fujifilm Holdings Corp <4901.T> said on Thursday that it had signed a manufacturing contract agreement with U.S.-based firm VLP Therapeutics for a COVID-19 vaccine formulation.

Fujifilm agrees manufacturing contract with VLP Therapeutics for COVID-19 vaccine

Fujifilm Holdings Corp said on Thursday it concluded a manufacturing contract agreement with VLP Therapeutics for a COVID-19 vaccine formulation.

Fujifilm's Avigan shown to be effective in Japanese Phase-3 trial for COVID-19

Fujifilm Holdings Corp said on Wednesday a late-stage study of its antiviral drug Avigan showed it reduced recovery times for COVID-19 patients with non-severe symptoms, boosting expectations for regulatory approval in Japan.

Philippines talking to Russian vaccine maker on trials, seeks 'complete dossier'

Philippine scientists were set on Wednesday to meet representatives of the Russian state research facility that developed a coronavirus vaccine, to discuss participation in clinical trials and access to its research data.

Japan's Fujifilm gets $265 million U.S. contract to boost output of potential virus vaccine

The United States has awarded a $265 million contract to a Texas facility of Japan's Fujifilm Holdings Corp to step up production of a coronavirus vaccine candidate, President Donald Trump said.

Fujifilm to partner with Dr. Reddy's to sell Avigan as COVID-19 treatment

Japan's Fujifilm Holdings Corp announced a deal with India's Dr Reddy's Laboratories and Dubai-based Global Response Aid (GRA) to sell its anti-flu drug Avigan for COVID-19 treatment globally excluding Japan, China and Russia.

Fujifilm to partner with Dr. Reddy's to sell Avigan overseas as COVID-19 treatment

Fujifilm Holdings Corp said on Wednesday it was partnering with Dr Reddy's Laboratories to sell the anti-flu drug Avigan in India and elsewhere to treat COVID-19, the respiratory disease caused by the coronavirus.

Japan's Fujifilm to spend $928 million to double capacity of Danish drug facility

(This June 10 story corrects second paragraph to say facility makes antibody drugs, not viral vaccines)

BRIEF-Tonix Pharma Reports Fujifilm Diosynth To Be Manufacturing Partner For Covid-19 Vaccine Candidate

* TONIX PHARMACEUTICALS ANNOUNCES FUJIFILM DIOSYNTH BIOTECHNOLOGIES TO BE MANUFACTURING PARTNER FOR COVID-19 VACCINE CANDIDATE TNX-1800 Source text for Eikon: Further company coverage:

Fujifilm shares fall after report Avigan not showing clear efficacy in some coronavirus trials

Shares of Fujifilm Holdings Corp fell on Wednesday after Kyodo news reported that so far there has been no clear evidence of efficacy for its drug Avigan in treating the novel coronavirus in some clinical trials.

Fujifilm shares fall after report Avigan not showing clear efficacy in some coronavirus trials

Shares of Fujifilm Holdings Corp <4901.T> fell on Wednesday after Kyodo news reported that so far there has been no clear evidence of efficacy for its drug Avigan in treating the novel coronavirus in some clinical trials.

BRIEF-Fujifilm's Anti-Flu Avigan Not Showing Apparent Efficacy In Coronavirus Treatment - Kyodo News

* FUJIFILM'S ANTI-FLU AVIGAN NOT SHOWING APPARENT EFFICACY IN CORONAVIRUS TREATMENT - KYODO NEWS, CITING SOURCES Source text : https://bit.ly/3bIfDVP

Tokyo confirms 15 new cases of coronavirus infection - Fuji TV

Tokyo confirmed 15 new cases of coronavirus infection on Monday, the first time in 42 days that the daily number has fallen below 20, Fuji TV reported the same day. (Reporting by Chris Gallagher; Editing by Toby Chopra)

Daito Chemix says will make ingredients for Fujifilm's Avigan drug

Daito Chemix Corp announced it had agreed to produce intermediate chemicals for the production of Fujifilm Holding Corp's Avigan drug.

BRIEF-Fujifilm Has Developed Chemical That Makes Possible Automated Coronavirus Testing In 75 Minutes - Nikkei

* HAS DEVELOPED CHEMICAL THAT MAKES POSSIBLE AUTOMATED CORONAVIRUS TESTING IN 75 MINUTES - NIKKEI

UPDATE 1-Japan to block foreign acquisitions of drug and ventilator makers - Nikkei

Japan plans to block foreign companies from acquiring domestic drug and medical equipment makers, to protect access to medicine and ventilators that have proven critical amid the coronavirus outbreak, a media report said on Wednesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up